Vuja De Sciences Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
M&A
Vuja De Sciences General Information
Description
Developer of cancer metastasis treatments designed to prevent the recurrence and spread of cancer. The company offers laboratory technologies and integrates comparative oncology for vulnerabilities of undetected microscopic tumours, utilizing a proprietary combination of drugs that disrupt their survival mechanisms, enabling oncology and canine patients to address significant unmet medical needs in cancer treatment.
Contact Information
Website
www.vujade-life.comCorporate Office
- 827 Bloomfield Street
- Unit 300
- Hoboken, NJ 07030
- United States
Corporate Office
- 827 Bloomfield Street
- Unit 300
- Hoboken, NJ 07030
- United States
Vuja De Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 28-Jul-2025 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 30-Oct-2023 | Completed | Clinical Trials - Phase 2 | |||
| 1. Later Stage VC (Series A) | 29-Nov-2022 | $2.98M | $2.98M | Completed | Clinical Trials - Phase 2 |
Vuja De Sciences Comparisons
Industry
Financing
Details
Vuja De Sciences Competitors (102)
One of Vuja De Sciences’s 102 competitors is Aro Biotherapeutics, a Venture Capital-Backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Volastra | Venture Capital-Backed | New York, NY | ||||
| Repertoire Immune Medicines | Venture Capital-Backed | Cambridge, MA | ||||
| HiberCell | Venture Capital-Backed | Roseville, MN |
Vuja De Sciences Patents
Vuja De Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023220082-A1 | Methods, compositions, and combinations for preventing or treating cancer recurrence | Pending | 18-Feb-2022 | ||
| EP-4479745-A2 | Methods, compositions, and combinations for preventing or treating cancer recurrence | Pending | 18-Feb-2022 | ||
| EP-4479745-A4 | Methods, compositions, and combinations for preventing or treating cancer recurrence | Pending | 18-Feb-2022 | ||
| US-20250161287-A1 | Methods, compositions, and combinations for preventing or treating cancer recurrence | Pending | 18-Feb-2022 | ||
| WO-2023158783-A2 | Methods, compositions, and combinations for preventing or treating cancer recurrence | Inactive | 18-Feb-2022 | A61K31/4545 |
Vuja De Sciences Signals
Vuja De Sciences FAQs
-
When was Vuja De Sciences founded?
Vuja De Sciences was founded in 2017.
-
Where is Vuja De Sciences headquartered?
Vuja De Sciences is headquartered in Hoboken, NJ.
-
What is the size of Vuja De Sciences?
Vuja De Sciences has 7 total employees.
-
What industry is Vuja De Sciences in?
Vuja De Sciences’s primary industry is Drug Discovery.
-
Is Vuja De Sciences a private or public company?
Vuja De Sciences is a Private company.
-
What is Vuja De Sciences’s current revenue?
The current revenue for Vuja De Sciences is .
-
How much funding has Vuja De Sciences raised over time?
Vuja De Sciences has raised $4.05M.
-
Who are Vuja De Sciences’s competitors?
Aro Biotherapeutics, Centrose, Volastra, Repertoire Immune Medicines, and HiberCell are some of the 102 competitors of Vuja De Sciences.
-
When was Vuja De Sciences acquired?
Vuja De Sciences was acquired on 28-Jul-2025.
-
Who acquired Vuja De Sciences?
Vuja De Sciences was acquired by Healx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process